Illumina, Inc.
Illumina Announces Acquisition of SomaLogic
Summary
On June 22, 2025, Illumina, Inc. announced its entry into a definitive Stock Purchase Agreement to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. This acquisition is expected to enhance Illumina's presence in the expanding proteomics market and accelerate its multiomics strategy. The transaction is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first half of 2026.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement